Immunovant, Inc. IMVT Income Statement
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| $456.66M+26.5% | $360.92M+69.5% | $212.93M+32.9% | $160.26M+57.4% | ||
| $76.24M-1.3% | $77.24M+34.8% | $57.28M+19.3% | $48.02M-11.4% | ||
| $532.9M+21.6% | $438.15M+55.0% | $282.71M+29.5% | $218.28M+39.9% | ||
| $532.9M+21.6% | $438.15M+55.0% | $282.71M+29.5% | $218.28M+39.9% | ||
| $25.33M+2.4% | $24.73M-0.9% | $24.95M+229% | $7.58M— | ||
| $2.18M+364% | $470K+147% | -$1.01M— | —— | ||
| -$505.39M-22.4% | -$412.95M-59.6% | -$258.77M-22.7% | -$210.95M-34.5% | ||
| —— | $890K+57.0% | $567K— | —— | ||
| -$505.61M-22.2% | -$413.84M-59.6% | -$259.34M-22.9% | -$210.96M-34.6% | ||
| -$2.78-1.8% | -$2.73-43.7% | -$1.90-11.8% | -$1.70-18.9% | ||
| -$2.78-1.8% | -$2.73-43.7% | -$1.90-11.8% | -$1.70-18.9% | ||
| 708.5M+19.9% | 591.1M+8.6% | 544.3M+12.3% | 484.8M+12.3% | ||
| 708.5M+19.9% | 591.1M+8.6% | 544.3M+12.3% | 484.8M+12.3% | ||
| $25.33M+2.4% | $24.73M-0.9% | $24.95M+229% | $7.58M— | ||
| $2.18M+364% | $470K+147% | -$1.01M— | —— | ||
| $456.66M+26.5% | $360.92M+69.5% | $212.93M+32.9% | $160.26M— | ||
| -$479.65M-23.7% | -$387.84M-66.0% | -$233.59M-15.0% | -$203.18M-29.7% | ||
| -$480.06M-23.7% | -$388.22M-66.0% | -$233.82M-15.0% | -$203.37M-29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immunovant, Inc. profitable?
- Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.
- What is Immunovant, Inc.'s earnings per share?
- Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.
- Where does Immunovant, Inc.'s income statement data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.